Poster Display Poster Display session

71P - Real-world Treatment Patterns and Clinical Outcomes for patients received Sintilimab (Sint) in First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) in China: A Multicenter Retrospective Observational Study (ID 163)

Presentation Number
71P
Lecture Time
12:30 - 12:30
Speakers
  • Yan Yu (Harbin, China)
Session Name
Poster Display
Room
Foyer mezzanine
Date
Thu, Dec 8, 2022
Time
12:30 - 13:15

Abstract

Background

Sint has been used to treat patients (pts) with advanced NSCLC. This observational study aims to describe the real-world use of Sint and to explore its real-world effectiveness in the first-line (1L) treatment of advanced NSCLC.

Methods

Pts with advanced NSCLC initiating 1L therapy with Sint between Aug 1st 2018 and Aug 1st 2020 in 4 tertiary hospitals in mainland China were included. Data in demographic and clinical characteristics, treatment patterns and outcomes were retrospectively collected through medical records. Descriptive analysis was used to describe the baseline characteristics and treatment patterns. Kaplan-Meier method was used to calculate the median progression-free survival (mPFS).

Results

102 pts (85.3% men) were included with mean age of 63.9±9.5 years (median follow-up time: 4.8 months (mo) (range 0.0-32.0)). The most commonly-used treatment regimen was Sint + platinum (Pt) + taxanes (56.0%) for squamous NSCLC (sqNSCLC) and Sint + Pt + pemetrexed (38.5%) for non-squamous NSCLC (nsqNSCLC) (Table). The mPFS was 15.8 mo (95% CI: 11.5-NA) and 12.0 mo (95% CI: 6.3-NA) respectively for sqNSCLC and nsqNSCLC pts. The mPFS was 17.0 mo (95% CI 11.5-NA) in sqNSCLC pts using Sint + Pt + taxanes as 1L therapy and 7.2 mo (95% CI: 0.7-NA) in nsqNSCLC pts. The ORR was 57.1% and 53.6% respectively for sqNSCLC and nsqNSCLC pts.

Baseline characteristics and treatment pattern of NSCLC

Total (N=102) sqNSCLC (N=50) nsqNSCLC (N=52)
Age (mean±SD), years 63.9±9.5 64.9±7.0 63.0±11.4
Male (%) 85.3 88.0 82.7
Stage at first diagnosis (%)
III 21.6 34.0 9.6
IV 42.2 28.0 55.8
Median of Sint cycle number 4.0 3.0 5.0
Treatment pattern (%)
Sint monotherapy 6.9 4.0 9.6
Sint + Pt + taxanes 36.3 56.0 17.3
Sint + Pt + pemetrexed 19.6 0.0 38.5
Sint + Pt + gemcitabine 5.9 12.0 0.0
Sint + Pt + anti-VEGF therapy + pemetrexed 5.9 0.0 11.5
Sint + others 25.5 28.0 23.1

Conclusions

For sqNSCLC pts with Sint as 1L therapy, taxanes and gemcitabine are more preferred, while for nsqNSCLC pts, pemetrexed is more often combined. The real-world effectiveness of 1L treatment of Sint for advanced NSCLC pts is promising from the study.

Legal entity responsible for the study

Eli Lilly China.

Funding

Lilly (Shanghai) Management Co., Ltd.

Disclosure

L. Zhang: Financial Interests, Personal and Institutional, Full or part-time Employment, employees of Lilly China and own Lilly stock shares: Eli Lilly China; Financial Interests, Personal and Institutional, Stocks/Shares, employees of Lilly China and own Lilly stock shares: Eli Lilly China. L. Liu: Financial Interests, Personal and Institutional, Full or part-time Employment, employees of Lilly China and own Lilly stock shares: Eli Lilly China; Financial Interests, Personal and Institutional, Stocks/Shares, employees of Lilly China and own Lilly stock shares: Eli Lilly China. J. Li: Financial Interests, Personal and Institutional, Full or part-time Employment, employees of Lilly China and own Lilly stock shares: Eli Lilly China; Financial Interests, Personal and Institutional, Stocks/Shares, employees of Lilly China and own Lilly stock shares: Eli Lilly China. W. Ding: Financial Interests, Institutional, Advisory Role, received Lilly’s sponsorship: Happy Life Technology. All other authors have declared no conflicts of interest.

Collapse